Depression

Boston, MA

170 Depression Trials near Boston, MA

Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
Power Preferred
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65

900 Participants Needed

Active on Power
This trial evaluates whether adding the investigational drug Osavampator (also known as NBI-1065845) to existing oral antidepressant therapy can improve depressive symptoms in patients with depression who aren’t adequately responding to their current antidepressant medication(s).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

200 Participants Needed

Active on Power
This trial evaluates whether adding the investigational drug Osavampator (also known as NBI-1065845) to existing oral antidepressant therapy can improve depressive symptoms in patients with depression who aren’t adequately responding to their current antidepressant medication(s).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

200 Participants Needed

Active on Power
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

220 Participants Needed

Active on Power

ABX-002-2001 for Depression

Boston, Massachusetts
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.  This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening (approximately 35 days)  2. Treatment period (42 days)  3. Follow-up (2 weeks post treatment)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

230 Participants Needed

Active on Power
This study is testing VLS-01, a treatment containing DMT that is placed in the mouth and dissolved, to see if it can quickly help people with depression who haven’t improved with other treatments. Participants will receive either 1 or 3 doses of VLS-01, with support throughout the study, to evaluate its safety and effectiveness.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

142 Participants Needed

Active on Power

SP-624 for Depression

Boston, Massachusetts
This trial is testing the efficacy of an investigational drug, SP-624 (study drug) to see how well it might work to treat major depressive disorder.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

456 Participants Needed

Psilocybin for Depression

Charlestown, Massachusetts
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

20 Participants Needed

Azetukalner for Depression

Boston, Massachusetts
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

450 Participants Needed

Solriamfetol for Depression

Boston, Massachusetts
This trial is testing solriamfetol, a medication that may help improve symptoms of depression. It targets adults with major depressive disorder (MDD) who do not have psychotic features. Solriamfetol works by affecting brain chemicals involved in mood regulation, potentially helping to improve mood and reduce depression symptoms.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

300 Participants Needed

NMRA-335140 for Depression

Boston, Massachusetts
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

332 Participants Needed

NMRA-335140 for Depression

Boston, Massachusetts
This trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

1000 Participants Needed

This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

2726 Participants Needed

The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large sample of matched historical controls. Patients will be recruited from an inpatient psychiatric unit. Eligible patients who provided informed consent will be enrolled in the study that will include a eight IV ketamine treatments, 13 esketamine treatment visits, seven long assessment visits, five short assessment visits, and daily surveys. The study will examine the feasibility, tolerability, and efficacy of repeated IV ketamine followed by esketamine, as well as predictors of treatment response.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

100 Participants Needed

This study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:40 - 60
Sex:Female

80 Participants Needed

AXS-05 for Depression

Boston, Massachusetts
This trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65

350 Participants Needed

This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64

10 Participants Needed

BI 1569912 for Depression

Roslindale, Massachusetts
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants are put into 4 groups randomly, which means by chance. Three of the 4 groups take different doses of BI 1569912 and 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2.5 months. During this time, they visit the study site at least 7 times. At the visits, doctors and their staff ask participants about their depression symptoms. At the end of the study, the results are compared between the groups to see whether the treatment works. The doctors also regularly check the general health of participants and take note of any unwanted effects.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65

224 Participants Needed

This trial tests aiTBS, a magnetic brain stimulation method, on patients with depression that hasn't responded to other treatments. The treatment uses magnetic pulses to reset brain activity and improve mood. Participants will receive aiTBS either guided by brain scans or by physical measurements of the head. Intermittent Theta Burst Stimulation (iTBS) is a newer form of repetitive Transcranial Magnetic Stimulation (rTMS) that has shown potential for faster and more intense effects in treating depression.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:22 - 80

40 Participants Needed

SPT-300 for Depression

Boston, Massachusetts
This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2

360 Participants Needed

Why Other Patients Applied

"I had a serious spinal cord injury four years ago, and my entire life turned upside down. I lost everything including a 10 year relationship. I became handicapped and part of that handicap is a mental handicap or I just can’t seem to find my happiness anymore. I go to events where everybody’s laughing, smiling, dancing, and having a good time, and I seem to just sit there like a bump on log. It feels like my spirit is broken. I want to feel happiness and motivation for life again."

YX
Depression PatientAge: 76

"I was first diagnosed with major depressive disorder and anxiety over twenty years ago. I have tried different medications. Had to come off medications due to pregnancies, and have worked through different side effects like weight gain, nausea, sleepiness, and the more severe where i have tried to claw my way out of my skin it itched so bad. I dont want other people to have to go through this and I wish I could be off of my medication for good but it just hasnt happened. IF something is out there to improve the life of an anxious and/or depressed person I'd like to be able to say I helped find it."

HD
Depression PatientAge: 46

"I have struggled with depression since I was a child. I have experienced about more than 6 major depressive episodes lasting at least 4 months since I was 7 years old. I have tried talk therapy, a plethora of medication, and nothing has worked long term. Medication and talk therapy helps me manage and reduce the length of depressive episodes but I am in search for alternative treatments. My depression has made completing a bachelors degree a major challenge."

UD
Depression PatientAge: 25

"I have struggled my entire life with depression. I feel like it took away half my life because I've been unable to truly feel the good times and people around me, like I'm numb. I would like to take part to see if it might help me, but I would also like to help others by doing this trial if I am accepted. I would love to enjoy life and truly feel the happy experiences that might come my way rather than observe them without feeling."

EW
Depression PatientAge: 45

"I’ve had depression for many years and been on a LOT of different medications. They work for awhile and then they just stop working. It’s very frustrating. I am very open to trying something new and different. Just looking to fight this, head on."

ZX
Depression PatientAge: 55

SPT-300 for Depression

Boston, Massachusetts
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

360 Participants Needed

Zelquistinel for Depression

Boston, Massachusetts
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64

164 Participants Needed

BHV-7000 for Depression

Boston, Massachusetts
This trial is testing a new medication called BHV-7000 to see if it is safe and well-tolerated over several months in people with Major Depressive Disorder. The goal is to help those who suffer from severe depression by potentially offering a new treatment option.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2

480 Participants Needed

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 65

20 Participants Needed

Chronic Obstructive Pulmonary Disease (COPD) is prevalent and debilitating chronic disease in Veterans. COPD is highly co-morbid with depression and anxiety conferring greater morbidity and mortality risk. Physical activity is a modifiable behavior that can improve COPD outcomes. However, to date, interventions targeting physical activity have not addressed the high comorbidity between COPD and depression and/or anxiety symptoms ("emotional distress") despite emotional distress predicting poorer response to physical activity interventions. This CDA-2 proposal will develop and test the acceptability and feasibility of an integrative physical activity and mental health intervention for Veterans with COPD, emotional distress, and low physical activity. The intervention will be delivered via VA Video Connect enabling access to care among Veterans with substantial barriers to hospital-based outpatient care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:40+

40 Participants Needed

This project explores whether heated yoga, sauna, and a mindfulness app reduce depressive symptoms
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

120 Participants Needed

tDCS for Depression

Boston, Massachusetts
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 70

200 Participants Needed

Therapy Dog Visits for Injury

Boston, Massachusetts
Animal assisted therapy (AAT) with dogs has been shown to be beneficial for a wide range of patients with both acute and chronic illnesses, including spinal cord injuries, heart failure, myocardial infarctions, strokes, cancer, post-traumatic stress disorder, and depression. Studies have also demonstrated that even in healthy adults, the presence of dogs is associated with physiologic changes such as increased pain threshold, decreased blood pressure, and decreased heart rate. However, few studies have investigated the role of AAT in the post-operative course in adults. This study will investigate the impact of therapy dog visits on pain and anxiety scores for trauma patients at Boston Medical Center (BMC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

Smoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors likely contribute to these disparities, and the increased burden of gender minority stress may also be driving higher prevalence rates of anxiety and depression, both of which are more common among TGD individuals and among those who smoke relative to comparison samples. This study will (1) explore the ways in which gender minority stressors and associated anxiety and depression compromise smoking cessation among TGD individuals, identifying elements in an existing smoking cessation intervention that need to be adjusted to meet their unique needs; (2) adapt an existing smoking cessation intervention for TGD individuals; and (3) evaluate the feasibility and acceptability of the adapted intervention in a pilot randomized controlled trial.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

100 Participants Needed

This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 39

15 Participants Needed

Know someone looking for new options? Spread the word